Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial

Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, Stowasser S, Distler J, Matucci-Cerinic M, Volkmann E, Kuwana M, Distler O (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Jörg Distler Professur für Molekulare Mechanismen der Organfibrose

Involved external institutions

McGovern Medical School US United States (USA) (US) Cleveland Clinic US United States (USA) (US) Boehringer Ingelheim Schweiz CH Switzerland (CH) University of Colorado System US United States (USA) (US) University of Washington US United States (USA) (US) Boehringer Ingelheim (France) FR France (FR) Boehringer Ingelheim Pharma GmbH & Co. KG DE Germany (DE) Università degli Studi di Firenze / University of Florence IT Italy (IT) University of California Los Angeles (UCLA) US United States (USA) (US) Nippon Medical School JP Japan (JP) Universitätsspital Zürich (USZ) CH Switzerland (CH)

How to cite

APA:

Mayes, M., Highland, K., Gahlemann, M., Fischer, A., Raghu, G., Girard, M.,... Distler, O. (2019). Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.

MLA:

Mayes, Maureen, et al. "Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2019.

BibTeX: Download